886361-98-4

Basic information

• Product Name: methyl 3-bromoH-imidazo[1,2-a]pyridine-6-carboxylate
• Synonyms: methyl 3-bromoH-imidazo[1,2-a]pyridine-6-carboxylate;IMidazo[1,2-a]pyridine-6-carboxylic acid, 3-broMo-, Methyl ester
• CAS NO: 886361-98-4
• Molecular Formula: C₉H₇BrN₂O₂
• Molecular Weight: 255.07
• EINECS: 604-604-1
• Mol File: 886361-98-4.mol
• Article Data: 2

Chemical Properties

• Melting Point: 162～163℃
• Appearance: /
• Density: 1.68±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 2.23±0.50(Predicted)
• CAS DataBase Reference: methyl 3-bromoH-imidazo[1,2-a]pyridine-6-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 3-bromoH-imidazo[1,2-a]pyridine-6-carboxylate(886361-98-4)
• EPA Substance Registry System: methyl 3-bromoH-imidazo[1,2-a]pyridine-6-carboxylate(886361-98-4)

Safety Data

• Hazardous Substances Data: 886361-98-4(Hazardous Substances Data)

Usage

General Description

Methyl 3-bromoH-imidazo[1,2-a]pyridine-6-carboxylate is a chemical compound with the molecular formula C9H7BrN2O2. It is a heterocyclic compound with a unique fused ring system, containing a bromo group and a carboxylate functional group. methyl 3-bromoH-imidazo[1,2-a]pyridine-6-carboxylate has potential applications in the field of medicinal chemistry and drug discovery, as it can serve as a building block for the synthesis of biologically active molecules. Its unique structure and reactivity make it a valuable intermediate in the synthesis of pharmaceuticals and agrochemicals. Additionally, its structural features make it a promising candidate for further research in the development of new pharmaceutical compounds and materials.

Upstream product

• 136117-69-6 methyl 6-imidazo<1,2-a>pyridinecarboxylate 

Downstream Products

• 886362-00-1 3-bromoimidazo[1,2-a]pyridine-6-carboxylic acid 

Relevant articles and documents

Lead optimization of imidazopyrazines: A new class of antimalarial with activity on Plasmodium liver stages

Imidazopyridine 1 was identified from a phenotypic screen against P. falciparum (Pf) blood stages and subsequently optimized for activity on liver-stage schizonts of the rodent parasite P. yoelii (Py) as well as hypnozoites of the simian parasite P. cynomolgi (Pc). We applied these various assays to the cell-based lead optimization of the imidazopyrazines, exemplified by 3 (KAI407), and show that optimized compounds within the series with improved pharmacokinetic properties achieve causal prophylactic activity in vivo and may have the potential to target the dormant stages of P. vivax malaria.